Unknown News

company, MRK

Unknown Market News

Moderna‑Merck Cancer Vaccine Trial Spurs MRK Rally to 52‑Week High

Merck shares surged after late‑stage melanoma mRNA vaccine results with Moderna drove stock to new 52‑week high amid oncology optimism.

Read the story

23d

Merck Shares Rally on Breakthrough mRNA Melanoma Trial with Keytruda Partner

Merck (MRK) stock jumps after a late‑stage trial of an mRNA therapy plus Keytruda met efficacy targets in high‑risk melanoma, marking a major pharma milestone.

13 Aug at 05:23

Merck's Strategic Moves and Market Performance: A Recent Overview

Merck's recent developments and stock performance analysis.

29 Jul at 12:32

Merck's Strategic Initiatives: Navigating Opportunities in the Pharmaceutical Landscape

Merck's strategic moves and market performance analyzed.

26 Jul at 20:07

Merck's Strategic Developments and Market Performance: A Recent Overview

An analysis of Merck's recent strategic moves and their impact on stock performance.

19 Jul at 20:05

Merck's FDA Approval of Lipfendra and Strategic Moves Propel Stock to New Heights

Merck's Lipfendra approval and strategic acquisitions boost stock performance.

12 Jul at 20:03

Merck's Recent Developments and Their Impact on Stock Performance

Analyzing Merck's strategic moves and stock fluctuations in the pharmaceutical and animal health sectors.